Antiplatelet Drugs Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Antiplatelet Drugs Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
复制标题
DOI：
10.1378/chest.11-2293
复制
发表时间：
2012-02-01
期刊：
影响因子：
9.6
通讯作者：
Weitz, Jeffrey I.
中科院分区：
文献类型：
--
作者：
Eikelboom, John W.;Hirsh, Jack;Weitz, Jeffrey I.
本文描述了阿司匹林、双嘧达莫、西洛他唑、噻吩吡啶和糖蛋白IIb/IIIa拮抗剂的作用机制、药代动力学和药效学。本文讨论了剂量、疗效和安全性之间的关系，并对随机临床试验的结果进行了机制概述。本文没有提供具体的管理建议，但强调了抗血小板治疗的重要实践方面，包括最佳剂量，在不同临床环境中单独使用抗血小板治疗或与其他抗血小板药物联合使用抗血小板治疗时获益和风险之间的可变平衡，以及尽管进行了这种治疗，但血小板反应性持续高的影响。
The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa antagonists. The relationships among dose, efficacy, and safety are discussed along with a mechanistic overview of results of randomized clinical trials. The article does not provide specific management recommendations but highlights important practical aspects of antiplatelet therapy, including optimal dosing, the variable balance between benefits and risks when antiplatelet therapies are used alone or in combination with other antiplatelet drugs in different clinical settings, and the implications of persistently high platelet reactivity despite such treatment.